Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Federico Cappuzzo, Michael McCleod et al.|The Lancet Oncology|2019Cited by 1.7k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Daniel S. Lieber et al.|Nature Medicine|2018Cited by 1.2k
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialEnriqueta Felip, H. Wakelee, Nasser K. Altorki et al.|Annals of Oncology|2023Cited by 251
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLCFederico Cappuzzo, Howard West, Michael McCleod et al.|Annals of Oncology|2018Cited by 58